CRISPR Therapies, Base Editing and Approvals — 2026-10-13
CRISPR Therapeutics shares surged 7.26% this week as investors positioned for imminent late-breaking data from its in-vivo editing pipeline. The company announced it will present Phase 1b results for CTX310, an ANGPTL3-targeting therapy, at the upcoming American Heart Association Scientific Sessions, marking a critical milestone for systemic gene editing.
CRISPR Therapies, Base Editing and Approvals — 2026-10-13
Top developments
CRISPR Therapeutics Stock Surges on In-Vivo Data Anticipation
On October 11, 2026, CRISPR Therapeutics (CRSP) stock climbed 7.26% following reports of promising gene-editing trial results and maintained Buy ratings from major banks like Bank of America, which trimmed targets slightly to $81 but kept a positive outlook. The market reaction was driven by the anticipation of clinical data for CTX310, the company’s investigational in-vivo CRISPR/Cas9 therapy targeting angiopoietin-related protein 3 (ANGPTL3). This move highlights the growing investor confidence in "off-the-shelf" in-vivo therapies compared to traditional ex-vivo approaches.
CTX310 Late-Breaking Data Set for AHA Sessions
On October 8, 2026, CRISPR Therapeutics officially announced that it will present late-breaking clinical data from the Phase 1b trial of CTX310 at the American Heart Association (AHA) Scientific Sessions 2026. The trial evaluates CTX310's ability to edit genes in vivo to lower lipid levels, with previous data suggesting significant reductions in LDL and triglycerides. This presentation is crucial as it represents one of the most advanced stages for a systemic base-editing or CRISPR therapy aimed at common metabolic diseases, potentially broadening the addressable market beyond rare genetic disorders.
Analysts See Significant Upside Ahead of Key Catalysts
Financial analysts are increasingly bullish on CRISPR Therapeutics ahead of its end-of-2026 catalysts. On October 9, 2026, Citi analysts projected a 60% upside potential for the stock, citing the pivotal role of the upcoming data readouts. The consensus is that the success of CTX310 and other pipeline assets will determine whether the company can transition from a rare-disease-focused entity to a leader in high-volume cardiovascular gene editing. This sentiment contrasts with earlier skepticism about the scalability of personalized medicine models.
Local view
No recent local-language media coverage specific to these October 2026 developments was available in the current research dataset.
Context & numbers
The financial context for this week's news includes CRISPR Therapeutics' Q2 2026 revenue of USD 10.2 million, a significant increase from USD 0.9 million in the same period a year prior, while net losses narrowed to USD 0.94 per share from USD 2.40. Analysts are closely watching the November data date for further gene-editing updates, which could serve as another catalyst before year-end.
On the radar
- AHA Scientific Sessions 2026: The actual presentation of CTX310 Phase 1b data at the American Heart Association meetings is the primary event to watch later this month, which will provide concrete figures on lipid reduction durability and safety in a broader patient population.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
